Free tool
FAERS Monitor: Jelmyto
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211728 or its brand name (Jelmyto, Mitomycin). Reports on generic versions are filed under their own applications.
Reports
3,208
Serious
2,668
83% of reports
Hospitalization
987
Death reported
398
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use384
- nausea165
- diarrhoea158
- fatigue118
- thrombocytopenia112
- vomiting111
- neutropenia109
- drug ineffective108
- rash107
- pancytopenia104
- disease progression100
- pyrexia95
- death93
- pain82
- leukopenia76
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 67 |
| 2005 | 77 |
| 2006 | 86 |
| 2007 | 96 |
| 2008 | 125 |
| 2009 | 79 |
| 2010 | 94 |
| 2011 | 137 |
| 2012 | 134 |
| 2013 | 129 |
| 2014 | 86 |
| 2015 | 112 |
| 2016 | 97 |
| 2017 | 86 |
| 2018 | 127 |
| 2019 | 160 |
| 2020 | 157 |
| 2021 | 186 |
| 2022 | 212 |
| 2023 | 148 |
| 2024 | 252 |
| 2025 | 342 |
| 2026 | 219 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,951 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancytopeniaSignal | 104 | 12.2 | 10.1 | 1,061 |
| leukopeniaSignal | 76 | 10.0 | 8.0 | 605 |
| thrombocytopeniaSignal | 112 | 6.6 | 5.5 | 526 |
| disease progressionSignal | 100 | 5.5 | 4.6 | 370 |
| neutropeniaSignal | 109 | 5.3 | 4.4 | 374 |
| off label useSignal | 384 | 2.9 | 2.6 | 488 |
| pyrexia | 95 | 1.8 | 1.5 | 34 |
| rash | 107 | 1.6 | 1.3 | 25 |
| diarrhoea | 158 | 1.6 | 1.4 | 37 |
| vomiting | 111 | 1.5 | 1.3 | 21 |
| nausea | 165 | 1.4 | 1.2 | 17 |
| fatigue | 118 | 1.0 | 0.8 | 0 |
| pain | 82 | 0.9 | 0.7 | 1 |
| death | 93 | 0.7 | 0.6 | 11 |
| drug ineffective | 108 | 0.5 | 0.4 | 45 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.